Fabino Enterprises Peer Comparison

Fabino Enterprises Ltd. shows poor financial metrics relative to its peers in the Pharmaceuticals & Drugs industry, indicating a lack of growth and profitability. Among its peers, Sun Pharmaceutical Industries Ltd. and Cipla Ltd. demonstrate robust profitability and growth metrics, marking them as industry leaders. Conversely, Fabino appears financially weak with no revenue and losses in cash flow, making it a significant underperformer in the sector.

• • Fabino Enterprises Ltd. has the lowest metrics across the board, with no revenue growth or profitability indicators.
• • Sun Pharmaceutical Industries Ltd. and Cipla Ltd. lead in profitability and growth, showcasing strong EPS and ROE.
• • Divi's Laboratories Ltd. faces challenges with declining revenue over three years despite decent profitability metrics.

• • Sun Pharmaceutical Industries Ltd.: Strong revenue growth (8.42% YoY), high profitability (ROE of 16.13%), and solid EPS growth.
• • Cipla Ltd.: Consistent revenue growth (13.28% YoY) and attractive valuation metrics (low PE of 23.73 and PEG of 0.35).